News

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

Announcement of Agreement on Company Split (Simplified Absorption-Type Split) of Japan Tobacco Inc.'s Pharmaceutical Business and Acquisition of Shares of Akros Pharma Inc. by Shionogi Inc. (Making it a Subsidiary)

ESCMID Global 2025: Shionogi presents real-world data demonstrating better clinical outcomes when Fetcroja^® / Fetroja^® (cefiderocol) is used as empiric or documented therapy as compared to salvage therapy for the treatment of Gram-negative bacterial infections

Shionogi Initiates New Drug Application Submission for Ensitrelvir for Post-Exposure Prophylaxis with the U.S. Food and Drug Administration

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial – Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

Approval for "Fetroja^®" (cefiderocol) in South Korea

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder

Shionogi Announces Positive Results from Phase 2 Trial of Respiratory Syncytial Virus Oral Antiviral Candidate S-337395

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations